Biomarkers and personalized therapy in chronic kidney diseases

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1051-1054

  Schena, Francesco Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Biomarkers; Chronic kidney diseases; Personalized therapy; Pharmacogenetics; Pharmacogenomics

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FC RECEPTOR; INTERLEUKIN 8 RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CHRONIC KIDNEY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOMICS; GENOTYPE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; METABOLOMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL DIALYSIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PROTEIN EXPRESSION; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; DISEASE COURSE; HIGH THROUGHPUT SCREENING; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOMICS; PHARMACOGENETICS; PROTEOMICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84904318798     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.922953     Document Type: Review

References (24)

1. Cernaro V, Trifirò G, Lorenzano G, et al. New therapeutic strategies under development to halt the progression of renal failure. Expert Opin Investig Drugs 2014;23(5): 693-709
2. Robin X, Creixell P, Radetskaya O, et al. Personalized network-based treatments in oncology. Clin Pharmacol Ther 2013;94: 646-50
3. Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: Towards personalized medicine. Heart Fail Rev 2014;19(3): 369-81
4. Pesce F, Pathan S, Schena FP. From omics to personalized medicine in nephrology: Integration is the key. Nephrol Dial Transplant 2013;28: 24-8
5. Lampreabe I, Gainza de los Rios FJ, Arrieta Gutièrrez A, et al. Toward personalized medicine in renal transplantation. Transplant Proc 2010;42: 2864-7
6. Pharmacogenomics a knowledge database. Available from: Www. pharmgkb.org
7. Pèrez-Oller L, Torra R, Badenas C, et al. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999;34: 273-8
8. Wang AY, Chan JC, Wang M, et al. Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. Kidney Int 2003;63: 1899-907
9. Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004;50: 2202-10
10. De Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: Current status and future directions. Transplant Rev 2008;22: 6-20
11. Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphateglucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005;78: 351-61
12. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008;67: 1724-31
13. Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009;10: 388
14. Zaza G, Pontrelli P, Pertosa G, et al. Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant 2008;23: 1673-81
15. Kottgen A, Kao WH, Hwang SJ, et al. Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies. BMC Med Genet 2008;9: 49
16. Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011;16(Supp 1): S22-30
17. Bruno S, Camussi G. Role of mesenchymal stem cell-derived microvesicles in tissue repair. Pediatr Nephrol 2013;28: 2249-54
18. Sallustio F, Costantino V, Cox SN, et al. Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvescicle-shuttled decorin. Kidney Int 2013;83: 392-403
19. Cox SN, Sallustio F, Serino G, et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010;78: 396-407
20. Cox SN, Sallustio F, Serino G, et al. Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 2012;82: 548-60
21. Dell'Oglio MP, Zaza G, Rossini M, et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. J Am Soc Nephrol 2010;21: 2157-68
22. Argilès A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013;8: E62837
23. Goek ON, Prehn C, Sekula P, et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 2013;28: 2131-8
24. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6: 287-93.